SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is experiencing extreme volatility due to recent CME Group margin requirement increases and impending Chinese export restrictions on silver, which are set to take effect. This has created a stark divide among traders, with many anticipating a massive short squeeze driven by perceived physical scarcity and industrial demand, while others warn of a speculative "pump and dump" and forced liquidations.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG is trending as its dedicated 'DOG Army' passionately advocates for its position as the leading Bitcoin-native memecoin, highlighting its unique permanence and direct link to Bitcoin's infrastructure. Community discussion is amplified by news of companies like C2 Blockchain ($CBLO) significantly expanding their $DOG treasury holdings, signaling growing institutional interest and long-term conviction.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is a prominent topic among crypto enthusiasts, driven by its narrative as Bitcoin's "digital silver" and intense discussions around critical technical support and resistance levels. The community is actively debating a potential major price movement, with many expressing strong bullish conviction despite market consolidation and challenging any bearish sentiment.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS, a new treatment for motion-induced vomiting, notable for being the first in decades and for not causing drowsiness. The community is actively discussing its broader potential as an add-on therapy for GLP-1 induced nausea and vomiting, fueling significant speculation about a potential buyout from a major pharmaceutical company. This approval, coupled with other imminent regulatory decisions for jet lag and an antipsychotic drug, positions Vanda as a key topic among investors.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending following reports that Meta Platforms is incorporating its Qwen AI model into a new AI initiative, with additional buzz around a potential large order for AMD's MI308 accelerators. Community sentiment is deeply split between those who view Alibaba as a generational AI investment with significant undervaluation and others who persistently label it a "value trap" due to competitive pressures and substantial AI-related spending. This ongoing debate reflects broader market uncertainty surrounding China's economic trajectory and the long-term profitability of its tech giants.

Radware Ltd. engages in the provision of application security and delivery solutions for multi-cloud environments. The company’s cloud application, infrastructure, and API security solutions use AI-driven algorithms for precise, hands-free, real-time protection from the most sophisticated web, application, and DDoS attacks, API abuse, and bad bots. It operates through the following segments: Radware’s Core Business and Hawks’ Business. The Radware’s Core Business segment engages in providing cloud security-as-a-service products, application and data center security solutions, and application availability services. The Hawks’ Business segment provides cloud security solutions, including threat detection, entitlement management, and posture management. The company was founded by Yehuda Zisapel and Roy Zisapel on May 16, 1996 and is headquartered in Tel Aviv, Israel.

Radware

Radware is trending as its AI-powered cloud cybersecurity solutions garner attention, notably with the company's discovery of a critical zero-click AI vulnerability. Accelerated growth in cloud recurring revenue and strategic global expansions are fueling community discussions around its significant potential within the rapidly evolving threat landscape, alongside high growth expectations reflected in its valuation.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is trending as the community highlights its deep strategic ties with Tether, including a significant ownership stake and substantial commitments for ad and cloud services. This partnership, alongside the acquisition of Northern Data AG greatly expanding Rumble's AI and cloud infrastructure, is fueling strong discussions about the stock being undervalued and ripe for a potential short squeeze given its high short interest.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics ($EKSO) is seeing a significant surge and exceptional trading volume following news of a proposed business combination with Applied Digital's Cloud business to form ChronoScale Corporation, focused on AI workloads. The community is actively debating the implications of this AI infrastructure play, with many highlighting its low float and anticipating further momentum from short squeezes. However, some voices express caution regarding potential dilution for existing shareholders and the long-term outlook of the combined entity.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is trending amid a significant surge in silver prices, fueled by increasing industrial demand and speculation that silver is playing catch-up with gold's rally. The community is buzzing with predictions of further explosive gains and a 'silver squeeze,' though some express caution about extreme volatility and the potential for a sharp correction in this leveraged commodity.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang is trending due to escalating controversy surrounding a significant data breach impacting millions of users and its perceived lack of transparency, drawing strong criticism from both Korean government officials and consumers. The community is vigorously discussing leadership's response and the potential for severe operational and financial repercussions, as mounting calls for boycotts and legal action cast a shadow over its future in its dominant market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>While the discontinued trial yielded early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates, Verastem CMO said.&nbsp;</li><li>Verastem said it will now focus its resources on the clinical development of VS-7375 in advanced NSCLC and other solid tumors.&nbsp;</li><li>VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.</li></ul> Shares of Verastem Oncology (VSTM) fell 2% after hours on Monday after the company said that it has decided to discontinue its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data.No more patients will be enrolled in the trial being conducted in collaboration with Amgen and those already enrolled can continue treatment as per the investigator's discretion, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251229302295/en/Verastem-Oncology-Provides-Update-on-RAMP-203-Phase-12-Clinical-Trial-for-Advanced-KRAS-G12C-Mutant-Non-Small-Cell-Lung-Cancer">said</a>. The trial was evaluating Avutometinib and Amgen’s Sotorasib in a “doublet combination” and also with Defactinib as a “triplet combination” in patients naïve to or previously treated with a KRAS G12C inhibitor, which is a targeted cancer drug that block the specific KRAS G12C mutation.The company said it is assessing opportunities to share data from the interim analysis in the future. &nbsp;<h2 class="st-heading-2">Fresh Focus</h2>Verastem said it will now focus its resources on the clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors while also evaluating Avutometinib plus Defactinib in combination with chemotherapy in first line metastatic pancreatic cancer.“While avutometinib plus defactinib combined well with a G12C inhibitor to drive early and sustained anti-tumor responses, next generation G12C inhibitors are establishing a new benchmark with higher response rates,” chief medical officer John Hayslip said.Hayslip added that VS-7375 demonstrated a 69% response rate in advanced KRAS G12D NSCLC.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VSTM jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed at ‘low’ levels.A Stocktwits user applauded the decision as “sound.”<stembedurl>https://www.stocktwits.com/Drew613/message/640355285</stembedurl>Another opined that the VS-7375 numbers are “very exciting” and said they could see why the company prioritized it over the discontinued trial.<stembedurl>https://www.stocktwits.com/Sawnchey/message/640352752</stembedurl><a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> has gained 50% this year and more than doubled over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-supplier-reportedly-slashes-contract-in-part-due-to-lower-than-expected-cybertruck-demand/cL7dT7ARExx">Tesla Supplier Reportedly Slashes Contract In Part Due To Lower-Than-Expected Cybertruck Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer

The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 

Equity

The company discontinued its trial in advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) following evaluation of interim data. 


<ul class="summary-bullets"><li>As of December 26, 72 deaths have occurred, the company said on Monday.</li><li>SELLAS had said in August that it expects the 80 events to occur by year-end.&nbsp;</li><li>GPS is SELLAS’ lead candidate licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) traded 17% higher on Monday after the company said that it is approaching the final analysis of its late-stage trial in Acute Myeloid Leukemia. &nbsp;The company is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding. GPS is SELLAS’ lead candidate licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.<h2 class="st-heading-2">Final Analysis Nears</h2>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Provides-Update-on-Pivotal-Phase-3-REGAL-Trial-of-Galinpepimut-S-GPS-in-Acute-Myeloid-Leukemia-AML/default.aspx">said</a> on Monday. SELLAS had said in August that it expects the 80 events to occur by year-end.“We appreciate the continued dedication of the patients, families, and investigators participating in the pivotal Phase 3 REGAL trial where survival times, fortunately for patients and caregivers, appear longer than expected,” said SELLAS CEO Angelos Stergiou. “While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results.”<h2 class="st-heading-2">Interim Analysis</h2>In August, an Independent Data Monitoring Committee completed a pre-specified analysis of the trial and issued a positive recommendation to continue the trial without modification. No safety concerns were identified, and available efficacy data were consistent with expectations for continued trial conduct, the company then said.The study completed enrollment in April 2024, with a total of 126 patients randomized.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user called the current price “absurd” and opined the stock is worth double digits. “Right this second! Not tomorrow, not next week, not a year from now but immediately right this very second…DOUBLE DIGITS!,” they wrote.<stembedurl>https://www.stocktwits.com/Mr_Anderson007/message/640327741</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has more than tripled this year and risen by about 239% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tonix-pharmaceuticals-to-meet-with-fda-in-2026-to-advance-experimental-lyme-disease-prevention-drug/cL75CPSRExm">Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study

The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.

<ul class="summary-bullets"><li>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.</li><li>The company licensed TNX-4800 from its developers at UMass Chan Medical School in September.</li><li>There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease.</li></ul>Tonix Pharmaceuticals Holding Corp. (TNXP) announced on Monday that it intends to meet with the U.S. Food and Drug Administration in 2026 to discuss the development of its experimental drug in the treatment of Lyme disease.The company licensed TNX-4800 from its developers at UMass Chan Medical School in September. It is being developed for annual seasonal use, as one subcutaneous administration in the spring to protect against Lyme disease through fall, or the entire tick season in the U.S., without relying on the recipient’s immune system to generate antibodies.<h2 class="st-heading-2">What Is Lyme Disease?</h2>Lyme disease is a bacterial infection caused by the bacterium Borrelia burgdorferi and spread by infected blacklegged ticks. It causes symptoms such as a bull's-eye rash, fever, fatigue, and headaches, and, if untreated, can spread to joints, heart, and brain.There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease. According to Tonix, it is the most common vector-borne infection in the United States, and its incidence is climbing each year.<h2 class="st-heading-2">Tonix Eyes Advancing The Drug</h2>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.“We believe a controlled human infection model (CHIM)3-5 study using Borrelia-infected ticks that mimics natural infection would be a potential path to demonstrating TNX-4800 efficacy for approval,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1606/tonix-pharmaceuticals-announces-program-updates-on-phase">said</a> CEO Seth Lederman. He added that the firm expects to have the investigational product ready for clinical trials by early 2027.<h2 class="st-heading-2">Registered Direct Offering</h2>Separately, the company also announced the pricing of a $20.0 million registered direct offering on Monday<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1607/tonix-pharmaceuticals-announces-pricing-of-20-0-million"> at about</a> $16.26 per share/warrant. &nbsp;The firm intends to use the net proceeds from the offering to fund the commercialization of its marketed products, the development of its product pipeline, and general working capital and corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TNXP stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.A Stocktwits user sounded optimistic about the stock.<stembedurl>https://www.stocktwits.com/ZenofWealth/message/640294827</stembedurl><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is down 51% this year and by about 55% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nasa-administrator-jared-isaacman-sees-us-return-to-moon-before-trump-presidential-term-expiry/cLeCD4iREDB">NASA Administrator Jared Isaacman Sees US Return To Moon Before Trump’s Presidential Term Expiry</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug

The company also announced the pricing of a $20 million registered direct offering. 

<ul class="summary-bullets"><li>The company’s uranium production in Pinyon Plain Mine in Arizona and La Sal Complex in Utah beat the top end of previously reported guidance by about 11%.&nbsp;</li><li>Energy Fuels now expects to sell 360,000 pounds of finished triuranium octoxide in the fourth quarter of 2025, more than double from 160,000 pounds expected earlier.</li><li>The rare earths company also announced the completion of two long-term uranium sales contracts with U.S. nuclear power-generating companies.</li></ul>Energy Fuels Inc. (UUUU) shares climbed over 5% in Monday’s premarket trade after the company announced that its finished uranium production, mined uranium ore production, and uranium concentrate sales for FY 2025 exceeded previously announced guidance.The company’s Pinyon Plain Mine in Arizona and La Sal Complex in Utah mined over 1.6 million pounds of uranium in 2025, beating the top end of previously reported guidance by about 11%.Meanwhile, its White Mesa Mill in Utah produced over one million pounds of finished triuranium octoxide, a uranium compound, in 2025, also exceeding the top end of previously reported guidance.<h2 class="st-heading-2">Guidance Update</h2>Energy Fuels said it expects to sell 360,000 pounds of triuranium octoxide in the fourth-quarter (Q4) of 2025, more than double the 160,000 pounds expected earlier and a 50% increase from third-quarter (Q3) 2025 levels. Total gross uranium sales revenue for Q4 2025 is expected to be about $27 million.Energy Fuels also announced the completion of two long-term uranium sales contracts with U.S. nuclear power generating companies that are expected to contribute to the company’s deliveries between 2027 and 2032.Pursuant to these contracts, Energy Fuels expects sales of 780,000 to 880,000 pounds of triuranium octoxide in 2026, and anticipates additional sales in the spot and term markets. For 2027 to 2032, the company’s current portfolio of six long-term contracts is estimated to deliver 2.41 to 4.41 million pounds of triuranium octoxide.Energy Fuels also expects its cost of goods sold to start declining in the first-quarter (Q1) of 2026 as low-cost Pinyon Plain uranium is added to its inventory.<h2 class="st-heading-2">Rare Earth Focus</h2>Rare earth elements and critical metals have been in focus this year after China restricted supply following President Donald Trump’s export tariffs. China controls roughly 70% of global mining and nearly 90% of processing.As a result, there has been a renewed interest in companies positioned to supply critical materials outside China. Meanwhile, demand for rare earth minerals has been climbing in the U.S. and worldwide as crucial components in EV battery production.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/UUUU">UUUU shares</a> trended in the ‘bearish’ territory amid ‘low’ message levels over the past day.<figure class="image"><img style="aspect-ratio:1311/154;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_at_6_11_39_PM_png_56f1a40f94.webp" alt="On Stocktwits, retail sentiment around UUUU shares trended in the ‘bearish’ territory amid ‘low’ message levels over the past day." width="1311" height="154"></figure>Shares of UUUU are up over 186% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Energy Fuels' White Mesa mill in Utah. (Photo by: Jim West/UCG/Universal Images Group via Getty Images)

Why Is UUUU Stock Rising Today?

The company said that its finished uranium production, mined uranium ore production, and uranium concentrate sales for FY 2025 exceeded previously announced guidance. 

<ul class="summary-bullets"><li>The company also announced that it does not plan on additional psychiatric clinical trials and intends to prioritize its resources for other therapeutic areas including immunology, obesity and epilepsy in 2026.</li><li>BHV-7000 failed to meet its primary endpoint in a pivotal Phase II/III clinical trial for bipolar disorder in March.</li><li>Last month, FDA refused to approve the company’s drug Vyglxia in the treatment of Spinocerebellar ataxia, sparking portfolio prioritization measures.</li></ul>Shares of Biohaven Ltd. (BHVN) slumped 17% after hours on Christmas eve after the company announced that its mid-stage proof-of-concept study evaluating BHV-7000 for the treatment of major depressive disorder did not show a reduction of depressive symptoms.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/biohaven-provides-update-from-phase-2-proof-of-concept-study-with-bhv-7000-in-major-depressive-disorder-302649251.html">said</a> that no reduction in depressive symptoms were observed in the trial over six weeks as compared with placebo though trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression.The drug was safe and well-tolerated with adverse events mostly mild and moderate in intensity and largely resolved spontaneously, the company said.The company also announced that it does not plan on additional psychiatric clinical trials and intends to prioritize its resources for other therapeutic areas including immunology, obesity and epilepsy in 2026.BHV-7000 failed to meet its primary endpoint in a pivotal Phase II/III clinical trial for bipolar disorder in March. The company, however, is continuing the study of the drug in adult focal epilepsy.<h2 class="st-heading-2">Other Setbacks This Year</h2>The company’s setbacks this year are not limited to its psychiatry pipeline. Last month, the U.S. Food and Drug Administration <a href="https://stocktwits.com/news-articles/markets/equity/bhvn-stock-tumbles-pre-market-after-fda-refuses-approval-for-neurodegenerative-disorder-drug/cL2q0wsREGi">refused</a> to approve its drug Vyglxia in the treatment of Spinocerebellar ataxia, a neurodegenerative disorder characterized by progressive loss of voluntary motor control and atrophy of the brain’s cerebellum and brainstem. In a letter, the FDA cited issues including potential bias, design flaws, lack of pre-specification, and unmeasured confounding factors in Biohaven’s drug studies.The company subsequently announced that it will focus on three late-stage, clinical programs with the greatest potential for value generation over the next year. It also initiated strategic portfolio and cost optimization across multiple programs to achieve an approximately 60% reduction in annual direct research and development spend.The company said last month that it may pause or delay non-priority programs to maintain its cash runway.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around BHVN stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user dismissed the negative update as “expected” and expressed optimism for the upcoming epilepsy trial. “Good things are to come here,” they wrote.<stembedurl>https://www.stocktwits.com/Dragonfire89/message/640093489</stembedurl>Yet another user sees the company’s investigational obesity drug being another interesting catalyst besides the epilepsy trial.<stembedurl>https://www.stocktwits.com/Reneejordan001/message/640092601</stembedurl><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/biohaven-provides-update-from-phase-2-proof-of-concept-study-with-bhv-7000-in-major-depressive-disorder-302649251.html">BHVN stock</a> is down by 71% this year and by about 70% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-dismisses-ideas-of-spacex-echostar-merger-in-road-to-going-public/cLetcgcREvr">Elon Musk Dismisses Ideas Of SpaceX-Echostar Merger In Road To Going Public: ‘No Reason To Cut Corners’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Biohaven logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts

The company said that no reduction in depressive symptoms were observed in the BHV-7000 trial over six weeks as compared with placebo. 

<ul class="summary-bullets"><li>Edgewise is now on track to deliver comprehensive efficacy and safety data from Part D of the mid-stage trial in the second quarter of 2026.</li><li>The company said that a single adverse event of new onset AF was reported in Part D of the trial but added that the investigator deemed it as not related to the study drug.</li><li>While Stifel believes the company’s updates still leaves questions on safety, Truist reiterated optimism for the drug’s potential in treating hypertrophic cardiomyopathy.</li></ul>Shares of Edgewise Therapeutics (EWTX) traded 20% higher on Wednesday morning after the company announced positive safety data from the ongoing multi-part mid-stage clinical trial of EDG-7500 in hypertrophic cardiomyopathy (HCM).Earlier this year, the company reported positive results from Part B and Part C 50 mg and 100 mg fixed dose cohorts of the trial in which EDG-7500 administration led to improvements in key HCM disease markers. Hypertrophic Cardiomyopathy (HCM) is a genetic heart condition where the heart muscle thickens, making it harder to pump blood out, stiffening the heart, and potentially causing irregular rhythms, often leading to fatigue, shortness of breath, chest pain, or fainting.<h2 class="st-heading-2">New Study Updates</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-completion-of-the-edg-7500-cirrus-hcm-phase-2-parts-b-and-c-and-favorable-interim-safety-results-from-the-ongoing-part-d-study-in-hypertrophic-cardiomyopathy-302649113.html">said</a> on Wednesday that it also evaluated a lower 25mg fixed dose in certain participants in Parts B and C and evidence of clinical activity was observed across key HCM disease markers. A favorable safety profile was observed with no clinically meaningful changes in left ventricular ejection fraction (LVEF) and no events of atrial fibrillation (AF), it added. &nbsp;The company also reported interim safety results from Part D of the study and said that EDG-7500 generally had a favorable safety profile and was well tolerated.“The safety profile observed with EDG-7500 to date, across both healthy volunteers and the CIRRUS-HCM trial, supports the potential use of EDG-7500 in diverse HCM patient populations,” the company said.The company, however, said that a single adverse event of new onset AF was reported in Part D of the trial but added that the investigator deemed it as not related to the study drug. The trial participant was not on active cardiac monitoring at the time and had a history of arrhythmias, including supraventricular tachycardia, the company said.Edgewise is now on track to deliver comprehensive efficacy and safety data from Part D of the mid-stage trial in the second quarter of 2026. It is looking forward to starting a late-stage trial by 2026-end.<h2 class="st-heading-2">Experts Are Divided</h2>Stifel thinks the update still leaves questions on safety that'll take more than additional open-label data to disprove. The analyst is now looking forward to longer-term/controlled late-stage data.As per Stifel, the next big catalyst for the stock is data from the late-stage trial being conducted by the company for its drug Sevasemten in patients with Becker muscular dystrophy, a rare, X-linked genetic disorder causing progressive muscle weakness, mainly in males. The results from the trial are expected in the fourth quarter of 2026.Truist, meanwhile, kept a ‘Buy’ rating and $46 price target on Edgewise Therapeutics following the company's updates. Truist remains bullish on the opportunity for EDG-7500 in both obstructive HCM and non-obstructive HCM given signs of efficacy in both patient groups, the analyst told investors in a research note.H.C. Wainwright, which has a $42 price target and ‘Buy’ rating on Edgewise, sees the data reinforcing the drug’s potential for differentiation.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EWTX rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/EWTX">EWTX stock</a> is down by 2% this year and by about 12% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/netflix-pushes-back-on-trc-capital-mini-tender-bid-at-below-market-price/cLesy0MREv0">Netflix Pushes Back On TRC Capital’s Mini-Tender Bid At Below-Market Price</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Edgewise Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout

The investigational drug EDG-7500 was generally well tolerated in the trial, the company said. 

<ul class="summary-bullets"><li>SELLAS released positive results from its Phase 2 clinical trial for an investigational leukemia drug in early December.&nbsp;</li><li>The company is also expected to release the final event-driven analysis for its galinpepimut-S (GPS) drug by the end of 2025.&nbsp;</li><li>Some retail investors anticipate a buyout or partnership in the near future based on its oncology drug pipeline.</li></ul>SELLAS Life Sciences Group, Inc. (SLS) stock has been on investors’ radar over the past few weeks after the company released positive results from its Phase 2 clinical trial for an investigational leukemia drug in early December.Shares of SLS are up over 78% in just a month and continue to rise as investors discuss the potential of the drug, forthcoming developments, and possibilities of an acquisition. The stock is up nearly 3% in Wednesday’s premarket trade at the time of writing.<h2 class="st-heading-2">Trial Updates</h2>The trial for the SLS009 drug involved combining it with azacitidine (AZA) and venetoclax (VEN) in patients diagnosed with relapsed or refractory acute myeloid leukemia with myelodysplastic-related changes (AML-MR).Patients in the study with limited prior treatment achieved a median overall survival of 8.9 months, outperforming the historical benchmark of approximately 2.5 months for this patient population. Results showed a 46% overall response rate across all participants and a 58% overall response rate in patients with one prior line of therapy.SELLAS said it plans to expand the study of SLS009 in combination with azacitidine and venetoclax among acute myeloid leukemia patients in the first quarter of 2026.Apart from these positive trial results, users are also anticipating more information about the company’s galinpepimut-S (GPS) drug. Earlier this year, SELLAS had said that it expects the final event-driven analysis for the drug to be completed and reported by the end of 2025.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around SLS stock has remained in the ‘bullish’ territory for over a week, and message volume stayed at ‘high’ levels. The volume of retail messages for the stock has jumped 680% in the past month.Apart from the drug discussions, users are also actively discussing the possibility of an acquisition.One user pointed to the potential for a buyout or partnership, citing recent examples such as Cidara Therapeutics, which was bought by Merck for $9.2 billion.<stembedurl>https://stocktwits.com/DSCallez/message/640053184</stembedurl>Another bullish user echoed the sentiment, saying they were looking past trial success and focusing instead on who the buyer could be.<stembedurl>https://stocktwits.com/Johnmtnb2018/message/640055860</stembedurl>A third user said that even if the company did not provide updates on the GPS drug by the end of the year, it was still performing better than anyone expected, and a longer wait would mean a higher buyout price.<stembedurl>https://stocktwits.com/BobWayne/message/640054317</stembedurl><a href="https://stocktwits.com/symbol/SLS">Shares of SLS</a> are up over 197% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About?

SLS Stock- Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 

Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 


<ul class="summary-bullets"><li>Ramaco will repurchase shares over 24 months.</li><li>It intends to purchase shares with available funds.</li><li>Ramaco had signed an umbrella CRADA with U.S. Department of Energy to accelerate the discovery, mining, processing, and creation of rare earths</li></ul>Ramaco Resources shares were in the spotlight on Wednesday after its board authorized a share repurchase program of up to $100 million over 24 months, a sign of the firm's strong financial position, even after a sharp rally this year. The announcement sent its shares up more than 6% in premarket trading.The company intends to purchase shares under the repurchase program opportunistically, using available funds, ensuring sufficient liquidity to fund its capital development program.“With the closing of Ramaco's previously announced $600-plus million (before fees) in capital raises in the second half of 2025, we are well-positioned. We can now pursue opportunities to unlock value and maximize shareholder returns,” said Randall Atkins, Chairman and CEO of Ramaco.<h2 class="st-heading-2">Strong Demand For Rare Earths Bodes Well For Ramaco</h2>Beyond capital returns, investors are tracking Ramaco’s push into rare earth minerals.&nbsp; Demand for rare earth minerals has been surging in the United States and globally, as they have become crucial for the production of EV batteries, play a vital role in the global transition to clean energy, and enable advanced defense systems. According to a McKinsey report, global demand for rare earths is projected to triple by 2035. &nbsp;Ramaco earlier also signed an Umbrella Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Energy's ("DOE") National Energy Technology Laboratory ("NETL"), in a bid to accelerate the discovery, mining, processing, and creation of rare earths and critical minerals and materials at its Brook Mine in Sheridan, Wyoming.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around METC trended in “extremely bullish” territory amid “extremely high” message volume.<figure class="image"><img style="aspect-ratio:628/76;" src="https://news.stocktwits-cdn.com/METC_PNG_278c3de7e2.webp" alt="Retail sentiment around METC trended in “extremely bullish” territory amid “extremely high” message volume." width="628" height="76"></figure> Ramaco Resources' stock has surged more than 57% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Samples of rare-earth minerals from Baiyun'ebo or Bayan Obo mining district are on display at the Institute of Geology and Geophysics, Chinese Academy of Sciences (IGGCAS) on May 17, 2025, in Beijing, China. (Photo by VCG/VCG via Getty Images)

After A Sharp Rally In 2025, Ramaco Is Doubling Down With $100M Share Buyback

Ramaco’s CEO said that, with $600 million-plus (before fees) in capital raises in the second half of 2025, the firm is well-positioned to pursue opportunities to unlock value and maximize shareholder returns.

<ul class="summary-bullets"><li>UBS cited Echostar’s pivot from a wireless operator to an investment company after its spectrum portfolio sales as a reason for a valuation change.&nbsp;</li><li>UBS also noted that EchoStar’s approximately 3% SpaceX stake represented a significant upside for the company.&nbsp;</li><li>Citi said that SpaceX’s potential $800 billion valuation could double the pre-tax cost basis of EchoStar’s stake.</li></ul>EchoStar Corp. (<a href="https://stocktwits.com/symbol/SATS">SATS</a>) shares were in focus on Tuesday after the company received two price target updates from UBS and Citi, both of which underscored the impact of its <a href="https://stocktwits.com/symbol/SPACEX">SpaceX</a> stake.UBS lowered EchoStar’s price target to $125 from $128 while maintaining a ‘Neutral’ rating on the shares, according to TheFly. And in a separate note, Citi raised EchoStar’s price target to $111 from $87 with a ‘Neutral’ rating, as seen in TheFly.<h2 class="st-heading-2">The SpaceX Impact</h2>UBS noted that EchoStar’s pivot from a wireless operator to an investment company after the sale of about 75%-80% of its spectrum portfolio for roughly $43 billion warranted a valuation shift. UBS assigned $11B to the remaining spectrum based on precedents, resulting in the revised price target.However, the firm added that the company’s 3% SpaceX stake, now implied at about $22B or roughly $65 per share assuming an $800 billion valuation, represented a significant upside versus prior marks. Meanwhile, Citi analyst Michael Rollins hiked EchoStar’s price target, citing recent reports that SpaceX’s upcoming public listing at an allegedly $800B could double the pre-tax value of the cost basis for its SpaceX shares that it would receive after its pending spectrum sales.<h2 class="st-heading-2">Spectrum Deals</h2>In September, EchoStar agreed to sell its AWS-4 and H-block spectrum licenses to SpaceX in a $17 billion cash-and-stock deal that would give the satellite company up to $8.5 billion in SpaceX stock. Some media reports have also suggested that SpaceX may go public through a reverse merger with Echostar.Apart from the SpaceX deal, EchoStar also agreed to sell about $23 billion worth of low-band and mid-band wireless spectrum to AT&amp;T in August. Together, the deals shift EchoStar’s long-term focus away from direct-to-device satellite constellations.<h2 class="st-heading-2">How Are Stocktwits Users Reacting?</h2>On Stocktwits, retail sentiment around EchoStar shares slid into the ‘bearish’ territory from ‘neutral’ a day ago, while message volume declined to ‘normal’ from ‘high’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1302/145;" src="https://news.stocktwits-cdn.com/Echostar_sentiment_png_7388af44d4.webp" alt="On Stocktwits, retail sentiment around EchoStar shares slid into the ‘bearish’ territory from ‘neutral’ a day ago, while message volume declined to ‘normal’ from ‘high’ levels at the time of writing." width="1302" height="145"></figure>Meanwhile, retail sentiment for SpaceX slipped into the ‘neutral’ territory from ‘bullish’ a day ago, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1295/161;" src="https://news.stocktwits-cdn.com/Tesla_sentiment_png_b6d54d6740.webp" alt="Retail sentiment for SpaceX slipped into the ‘neutral’ territory from ‘bullish’ a day ago, while message volume remained at ‘high’ levels." width="1295" height="161"></figure>Shares of EchoStar are up over 378% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the EchoStar Corporation (Echo Star) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

EchoStar’s SpaceX Stake Is Driving UBS, Citi Price Target Revisions

UBS lowered EchoStar’s price target to $125 from $128 while Citi raised the firm’s price target to $111 from $87, according to TheFly.

<ul class="summary-bullets"><li>The drug is now expected to be available in the U.S. in the second half of January 2026.</li><li>The prescribing information for the drug includes a warning for the risk of heart failure due to systolic dysfunction.</li><li>Myqorzo is available only through a restricted program under a risk evaluation and mitigation strategy (REMS) because of the risk of heart failure.</li></ul> Shares of Cytokinetics, Incorporated (CYTK) soared as much as 7% after hours before paring back gains on Friday after the company said that its drug Myqorzo for the treatment of adults with thickened heart muscle has been approved by the U.S. Food and Drug Administration.The agency approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy and aimed at improving functional capacity and symptoms. Symptomatic obstructive hypertrophic cardiomyopathy means the individual has a thickened heart muscle that blocks blood flow out of the heart, causing symptoms like shortness of breath, chest pain (especially with exertion), palpitations, dizziness, fatigue, and fainting.The approval marks the company’s first by the FDA. “I’m pleased that the approved label and REMS reflect the distinct characteristics of Myqorzo including a straightforward, flexible dosing regimen, no requirement for drug-drug interaction monitoring and a predictable safety profile,” CEO Robert I Blum <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/19/3208724/35409/en/Cytokinetics-Announces-FDA-Approval-of-MYQORZO-aficamten-for-the-Treatment-of-Adults-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-to-Improve-Functional-Capacity-and-Sym.html">said</a>.The drug is now expected to be available in the U.S. in the second half of January 2026.<h2 class="st-heading-2">Risks Associated</h2>The prescribing information for the drug includes a warning for the risk of heart failure due to systolic dysfunction. Echocardiogram assessments are required prior to and during treatment with Myqorzo to monitor for systolic dysfunction, the company said. The initiation of the drug is not recommended for patients with low Left Ventricular Ejection Fraction (LVEF). LVEF refers to the percentage of blood pumped out of the heart's main pumping chamber, the left ventricle, with each heartbeat.Myqorzo is available only through a restricted program under a risk evaluation and mitigation strategy (REMS) because of the risk of heart failure.FDA approved the drug on the basis of results from a late-stage trial in which Myqorzo improved exercise capacity and reduced symptoms. The drug was also well tolerated in the study with no instances of worsening heart failure or treatment interruptions. Treatment emergent serious adverse events occurred in 5.6% of patients on the drug and 9.3% of patients on placebo.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CYTK stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user highlighted that the recommended monitoring during the drug’s use is “pretty reasonable.”<stembedurl>https://www.stocktwits.com/kgpittm/message/639758721</stembedurl>Another expressed surprise at the stock trading in the red despite the “great news.”<stembedurl>https://www.stocktwits.com/Kim_Jong_Moon/message/639763223</stembedurl><a href="https://stocktwits.com/symbol/CYTK">CYTK stock</a> has risen 33% this year and by about 34% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/atai-beckley-supernus-jump-as-wall-street-flags-psychedelics-tailwinds-from-trump-marijuana-order/cLe02tNREtb">Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Cytokinetics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious?

The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

IWMW
iShares Russell 2000 BuyWrite ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWMW News

IWMWiShares Russell 2000 BuyWrite ETF